STOCK TITAN

Revelation Biosciences Inc - REVB STOCK NEWS

Welcome to our dedicated news page for Revelation Biosciences (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revelation Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revelation Biosciences's position in the market.

Rhea-AI Summary
Revelation Biosciences announces positive preclinical data for Gemini formulation, demonstrating therapeutic potential in multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary
Revelation Biosciences CEO to present at 2023 ROTH Healthcare Opportunities Conference on Oct 12. One-on-one investor meetings scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
Rhea-AI Summary
Revelation Biosciences appoints Dr. Lakhmir Chawla to its Board of Directors. Dr. Chawla brings expertise in nephrology, critical care medicine, and drug development. Positive impact on stock expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
management
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) reported its financial results for the three and six months ended June 30, 2023. The company had $15.7 million in cash and cash equivalents as of June 30, 2023, compared to $5.3 million as of December 31, 2022. Net cash used for operating activities for the six months ended June 30, 2023, was $3.6 million, a decrease from $8.5 million for the same period in 2022. The net loss for the three months ended June 30, 2023, was $1.4 million, compared to a net loss of $1.8 million for the same period in 2022. Net income for the six months ended June 30, 2023, was $4.7 million, primarily due to the change in fair value of the warrant liability creating an $8.2 million gain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
conferences
Revelation Biosciences Inc

Nasdaq:REVB

REVB Rankings

REVB Stock Data

3.40M
1.63M
0.32%
1.96%
2.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego

About REVB

we develop immunologic therapeutics and diagnostics designed to make the world a healthier place